Methicillin (sodium salt) (Synonyms: BRL 1241,SQ 16,123,X 1497) |
| Catalog No.GC10917 |
Methicillin is a narrow-spectrum beta-lactam antibiotic that acts by inhibiting penicillin-binding protein (PBP). It can be used to treat sepsis and various inflammation.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 132-92-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Methicillin is a narrow-spectrum beta-lactam antibiotic that acts by inhibiting penicillin-binding proteins (PBP). Methicillin has a good effect on penicillinase producing S. aureus. Methicillin is not absorbed orally and must be administered by injection. It can be used to treat septicemia, endocarditis, pneumonia, meningitis, brain abscess, pericarditis, urinary tract infection, skin soft tissue infection, osteomyelitis, pseudomembranous enteritis. Methicillin can also be used to screen for resistant strains [1-3].
Methicillin (20 μg/mL; 24 h) results in a rapid decrease in CFU of S. aureus[4]. Methicillin (0-100 μg/mL; 24 h) has a high killing effect on CI-G S. aureus. Strain [5].
Methicillin (intramuscular administration; 40 mg/kg every 6 h; 5 days) reduced mortality in in S. aureus.-infected rabbits[4]. Methicillin (9 μg/ml; 4days; 0.5 ml/day) and a bismuth metal-organic framework (Bi-MOF) can synergistically enhance the therapeutic effect and inhibit the recurrence of infection in the tolerant S. aureus-induced murine subcutaneous infection model [6].
References:
[1]. Katsipis G, Pantazaki AA. Serrapeptase impairs biofilm, wall, and phospho-homeostasis of resistant and susceptible Staphylococcus aureus. Appl Microbiol Biotechnol. 2023 Feb;107(4):1373-1389. doi: 10.1007/s00253-022-12356-5. Epub 2023 Jan 13. PMID: 36635396; PMCID: PMC9898353.
[2]. Khoshnood S, Heidary M,et,al. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomed Pharmacother. 2019 Jan;109:1809-1818. doi: 10.1016/j.biopha.2018.10.131. Epub 2018 Nov 26. PMID: 30551435.
[3]. Xie X, Tong X, et,al. Use of mouse primary epidermal organoids for USA300 infection modeling and drug screening. Cell Death Dis. 2023 Jan 11;14(1):15. doi: 10.1038/s41419-022-05525-x. PMID: 36631452; PMCID: PMC9833019.
[4]. Carrizosa J, Santoro J, et,al. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin. Antimicrob Agents Chemother. 1978 Jan;13(1):74-7. doi: 10.1128/AAC.13.1.74. PMID: 626493; PMCID: PMC352187.
[5]. Banerjee S, Sionov RV et,al. Anandamide alters the membrane properties, halts the cell division and prevents drug efflux in multidrug resistant Staphylococcus aureus. Sci Rep. 2021 Apr 22;11(1):8690. doi: 10.1038/s41598-021-88099-6. PMID: 33888802; PMCID: PMC8062478.
[6]. Yuan, Kai et al. “Multi-roles of nanoscale bismuth metal-organic frameworks: Infectious photoacoustic probe and inhibitor of antibiotics tolerant bacteria via targeting endogenous H2S.” Nano Today (2022): n. pag.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *